@Dongen en Co.:
Quote:
“DDW 2015 Poster Schedule
as it relates to Exact Sciences:
Saturday, May 16 at 9:30 a.m., Hall C
Prevalence of DNA Biomarkers in Fecal Immunochemical Test Positive and Negative Colorectal Cancers
Author available for Q&A: Barry M. Berger, Exact Sciences
Cost-effectiveness analysis of stool DNA or colonoscopy for colorectal neoplasia surveillance in patients with ulcerative colitis
Author available for Q&A: David A. Ahlquist, M.D., Mayo Clinic
Molecular Detection of Colorectal Neoplasia: Do Markers that Target Acquired DNA Alterations in Sporadic Cases also Discriminate Lynch Syndrome Cases?
Author available for Q&A: David A. Ahlquist, M.D., Mayo Clinic
Sunday, May 17 at 9:30 a.m., Hall C
Novel Epigenetic Markers for Detection of Esophageal Cancer: Selection By Whole Methylome Sequencing and Tissue Validation
Author available for Q&A: David A. Ahlquist, M.D., Mayo Clinic
Test Performance Characteristics of Multi-Target Stool DNA Testing in African Americans and Caucasians
Author available for Q&A: Barry M. Berger, Exact Sciences”
En daarnaast volgende quote:
“Another fantastic presentation given by KC this afternoon
so it just wrapped up... at the investors conference in June they will be talking about the pipeline .. KC mentioned esophogeal, pancreatic, and said there is one more... nobody in the audience followed up with a question. He talked about the compliance problem with colonoscopy and FIT. He mentioned the possibility of TV advertising down the road.. they will not be budging on price to commercial payors…”
En dan dit nog:
“Interesting that KC said there was one more screen, with elaborating. I would hope this is for lung cancer since it has the highest incidence rate, and I suspect is more treatable than esophageal or pancreatic cancer. The higher incidence rate would also make it likely to require a smaller FDA study to detect the same number of cancers”
En dan iets van Dr. Groen zelf (niet via Exact Sciences):
In terms of what’s next, Groen notes that “MDxHealth has developed a liquid biopsy epigenetic test called ConfirmMDx for Bladder Cancer. Data from a clinical utility study using the test is scheduled for read-out in 2015. ConfirmMDx for Bladder Cancer is performed on urine samples to rule out bladder cancer in patients diagnosed with hematuria, who are traditionally followed with cytology and cystoscopy.”: